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What is collateral sensitivity?
Collateral sensitivity (CS) is an evolutionary trade-off between antibiotic resistance mecha-
nisms in bacteria and describes a situation where antibiotic resistance to 1 antibiotic confers
increased susceptibility to another antibiotic. CS typically means that inhibition of growth can
be achieved with lower concentrations of antibiotic (the strain has a reduced minimal inhibi-
tory concentration (MIC)). For bactericidal antibiotics, CS can also mean the faster and stron-
ger killing of the resistant bacterium, compared with one that does not carry the resistance
mechanism [1]. A prominent example of CS is the>16-fold lower MIC of tigecycline-resistant
Escherichia coli for nitrofurantoin where resistance to tigecycline and sensitivity to nitrofuran-
toin are caused by a mutation of the lon gene [2]. CS has been described for various chromo-
somal mutations [3], resistance plasmids [4], and resistance genes [5].
It is important to differentiate the genetically based CS effects from related physiological
phenomena that cause a similar increase of antibiotic efficacy. Antibiotic synergy refers to the
nonlinear increase of inhibition when antibiotics are applied in mixture [6], and negative hys-
teresis refers to a transient increase of antibiotic efficacy to 1 drug after a short preceding expo-
sure to another drug [7]. In contrast to CS, synergy and hysteresis both involve physiological
responses to drug exposure without any associated genetic changes. In this article, we focus
entirely on CS, its causative mechanisms, and the therapeutic potential of the phenomenon.
Why care about CS?
Resistance to antibiotic treatment is increasing due to the continued selection for less-susceptible
genetic variants in clinical and nonclinical environments. Resistant pathogens may cause a bacte-
rial infection that is hard to treat, and new resistance mechanisms may emerge during infection
as an evolutionary response to antibiotic therapy. The mechanisms by which these variants resist
inhibition from antibiotics are quite well understood and include (1) the reduced penetration of
the cell envelope; (2) the chemical destruction of antibiotic by specialized proteins; (3) metabolic
bypass of antibiotic targets; and (4) the modification of target structures that reduce binding [8].
In contrast, genetic mechanisms that increase the inhibitory effect of antibiotic treatments, as
observed for CS, are less understood. When understood, the concept of CS could be applied as a
last-resort treatment for pathogens with a matching resistance mechanism. Alternatively, CS
could be included in treatment designs as a mechanism to reduce/prevent resistance emergence.
How does CS work?
A mechanistic understanding of CS may be inspired by our present knowledge of resistance.
Applying the rule of inversion to described resistance mechanisms, we arrive at several
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potential sensitivity mechanisms (Fig 1). The CS of a resistance mechanism may result from
an increased concentration of active antibiotic at the target structure, as attained by either an
(1a) increased penetration of the cell envelope; (1b) reduced efflux of the antibiotic; or (2) the
formation of chemically more active antibiotic through the activity of specialized proteins.
Alternatively, it may result from (3) modified cellular functions and regulatory pathways that
increase the toxic effects of the antibiotic, or (4) the increased binding of antibiotic to modified
target structures. In addition to these effects, a false-positive CS signal may result from a gener-
ally weak growth ability of resistant pathogens even in the absence of treatment (the fitness
cost of resistance). Despite abundant theoretical explanations, experimental data are still rare.
The first sensitivity mechanism to be understood is the generally 2- to 4-fold lower MIC of
aminoglycoside-resistant E. coli to several classes of antibiotics (beta-lactams, fluoroquino-
lones, chloramphenicol, doxycycline, tetracycline) that is caused by mutations in the ion
Fig 1. Mechanisms of collateral sensitivity. Schematic illustration of resistance (top left) and collateral sensitivity (top
right) of a strain with resistance mechanism against antibiotic R. The resistant strain is indicated with a dashed line,
and the susceptible wild-type strain with a solid line. Yellow shading indicates increased inhibitory activity of antibiotic
A. The inhibitory effect of A that is generated upon binding of target structure T may be increased by several
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transport protein trkH [3]. The uptake of aminoglycoside antibiotics into the cell requires a
high proton motive force (PMF), and the mutation in trkH reduces the PMF, explaining resis-
tance to aminoglycoside. The activity of the major efflux pump system AcrAB-TolC is also
driven by PMF, so that as a lateral effect, the trkH mutation reduces the expulsion of several
classes of antibiotics, explaining the increased sensitivity through mechanism 1b [3].
However, sensitivity mechanisms can be more specific to the antibiotic. The antibiotic
nitrofurantoin is a prodrug that for activity requires chemical activation inside the cell by the
nitroreductase enzymes NfsA and NfsB. A recent study could link the CS to nitrofurantoin of
mecillinam-resistant E. coli with mutations in spoT to the increased expression of nitroreduc-
tase enzyme NfsB [2]. The same mechanism also conferred nitrofurantoin sensitivity in a tige-
cycline-resistant lon mutant of E. coli and a protamine-resistant hemL mutant of Salmonella
enterica [2]. Intriguingly, several additional sensitivity mechanisms contributed to the total
collateral effect in the lon and hemL mutants. The hemL mutant showed increased uptake of
nitrofurantoin, according to sensitivity mechanism 1a. The lon mutant provided an interesting
case of mechanism 3 and deserves a more detailed account.
Activated nitrofurantoin causes damage to DNA, causing cells to activate a native DNA-
repair system designated the lexA-dependent SOS response [9]. As part of the SOS response,
cells produce the SulA protein that stops growth during the repair process by inhibiting the
ring polymerization of the cell division protein FtsZ [10,11]. SulA is degraded by the Lon pro-
tease [12], and cell growth resumes a short while after the DNA damage is repaired. However,
in a lon mutant, accumulated SulA is not degraded and, consequently, cells stay locked in the
nondividing SOS state, explaining its increased sensitivity to nitrofurantoin. When cells are
experimentally equipped with noninducible alleles of lexA, they recover approximately two-
thirds of their total>16-fold reduction in MIC [2]. This example demonstrates the complexity
of CS mechanisms.
Finally, recent work provides an example for mechanism 4 [5]. The beta-lactamase gene
CTX-M-15 is present in several clinically relevant resistance plasmids. Beta-lactamases are
enzymes that can hydrolyse the antibiotic and chemically inactivate it. The mutation N135D
in this gene increases the MIC to the beta-lactam mecillinam 50-fold, but decreases the MIC to
cefotaxime, a slightly different beta-lactam, 20-fold [5]. The linked changes in sensitivity are
likely explained by noncompatible adjustments of the antibiotic binding site in the protein [5].
Together, these studies provide a glimpse at the fascinating genetic mechanisms behind CS.
They highlight how research of CS can increase our general understanding of bacterial
physiology.
How to use CS?
One key question regarding CS is how one could potentially exploit it in clinical settings to
increase efficacy and/or reduce resistance evolution. Since CS has several potentially useful
effects, e.g., (1) inhibition of growth with lower concentrations of antibiotic and (2) faster and
stronger killing of a resistant bacterium (compared to the susceptible), it could be applied to
both increasing efficacy and/or reducing the rate of resistance evolution. One potential appli-
cation are antibiotics where toxicity is an issue (e.g., aminoglycosides, vancomycin, colistin),
and the drug concentration should be kept as low as possible without compromising efficacy.
Thus, in cases when the infection is caused by a bacterium that carries a resistance to another
drug that increases susceptibility to any of these toxic antibiotics (which is expected be quite
rare), a lower concentration could be used for treatment. The second, more conceivable clini-
cal application that has received the most interest, is to use 2 drugs which show CS (preferably
reciprocal CS; i.e., resistance to antibiotic 1 increases susceptibility to antibiotic 2 and vice
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versa) in combination or sequentially in a temporal cycling scheme to reduce the rate of resis-
tance evolution. Several studies have shown that both combination or sequential use can
reduce the rate of resistance evolution under specific laboratory conditions [13–15]. However,
in vitro studies also highlighted variability of the evolutionary trade-off between experimental
replicates (e.g., [16–18]). While the average trade-off was CS, for certain antibiotic pairs, the
phenotype of independent replicates varied from strong CS to cross-resistance, as explained by
the fixation of alternative resistance mechanisms or alleles [16–18]. The resulting collateral
variation is expected from the stochastic supply of mutations, especially under small popula-
tion sizes and wide mutation spaces [16], and may considerably complicate the utility of CS
for therapy.
Is CS clinically applicable?
For CS to become more than an interesting example of an evolutionary trade-off, it needs clin-
ical testing. There are several examples of multidrug therapies that are in clinical use, e.g., for
HIV, malaria, and tuberculosis infections, demonstrating their utility for certain types of infec-
tions. However, the effectiveness of these combinations is not connected to CS per se (even
though it might inadvertently occur) but rather with a general suppression of the likelihood of
resistance evolution and/or increasing efficacy by combining antibiotics with different phar-
macodynamic/pharmacokinetic properties.
To our knowledge, no clinical study has prospectively tested the impact of CS on resistance
evolution, but a few papers have measured resistance development (mostly in P. aeruginosa)
under laboratory conditions and inferred expected clinical effects. One important study found
agreement of laboratory-evolved CS with the population dynamics of P. aeruginosa resistance
mutations in a hospitalized patient [19]. The monitored infection contained several resistant
subpopulations, whose relative frequency changed dramatically during treatment and, impor-
tantly, as expected from lab-evolved CS in the PAO1 strain and several clinical strains [19].
This case example indicates an overlap of resistance dynamics during clinical treatment and
laboratory “forecasting.” Comparative laboratory adaptation of P. aeruginosa with 38 different
drug mixtures showed that slow adaptation was significantly associated with CS [13], and
another study [14] showed that a CS treatment of resistant clones selects for new resistance
mechanisms that can disrupt the first resistance mechanism, causing resensitization in alter-
nating treatments. In this case, the resensitization depended on treatment order and was char-
acteristic for aminoglycoside to beta-lactam switches, but not the reverse switches [14]. A
study of tobramycin-ceftazidime showed that ceftazidime selects pyomelanogenic tobramycin-
hypersusceptible mutants and that this trade-off allows tobramycin/ceftazidime alternation to
drive extinction of resistant populations [15]. The evolution of CS is also dependent on the
environment as shown by a comparison of Acinetobacter baumannii evolving resistance to cip-
rofloxacin in culture versus biofilm [20] where CS to cephalosporins was only observed under
evolution in biofilms.
In contrast to the above studies, there is also evidence for the absence of useful evolved CS
patterns in clinical isolates. One study showed for isolates adapted to antibiotics in the lung of
cystic fibrosis patients [21] that resistant clinical isolates do not show consistent sensitivities to
other antibiotics, as is usually seen for vitro evolution experiments. The explanation for this
discrepancy is unclear, but it could be related to differences in antibiotic selective pressures
and mutational spectra or that adaptation to other selective pressures in vivo abrogates CS and
makes it evolutionary transient.
Based on the above finding, a priori one can imagine a number of complications that could
reduce the usefulness of CS and that need to be studied. These include (1) the effect size (how
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much is sensitivity increased), which is generally quite small, <5-fold [1,3], even though the
effects can also be more pronounced [22]; (2) the evolutionary conservation of CS (or lack
thereof) [23,24] within a species; (3) the lack of data showing its occurrence for horizontally
transferred genes (prior studies focused on mutational resistance); (4) the prevalence and
effectiveness of various types of escape mutants that could abrogate CS [14,21]; and (5) the
clinical relevance of the combinations of antibiotics and resistance mechanisms that have been
studied during laboratory experiments (e.g., the toxicity of certain drugs that are tested in labo-
ratory settings constrains their clinical application) [21,23].
In conclusion, the phenomenon of CS shows a number of useful characteristics under labo-
ratory conditions and has revealed several novel links between different resistance mechanisms
and antibiotic action. However, the clinical application of CS remains unclear, and addressing
it will require prospective clinical treatment studies to examine its ability to increase efficacy
and/or reduce the rate of resistance development. Until such data are available, CS will remain
an interesting biological phenomenon in search of a clinical application.
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